TriangleNCT04639219 · OUTCOME
Percentage of Participants Alive at 6 and 12 Months
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- At Months 6 and 12
What was measured
Percentage of participants alive at 6 and 12 months are reported. It was calculated using the Kaplan-Meier technique. CI for median PFS derived based on the Brookmeyer-Crowley method.
Analysis population: The FAS consisted of all participants who received at least 1 dose of study treatment.
Groups in this outcome
T-DXd
Participants harboring tumors with specific HER2 activating mutations received T-DXd 5.4 mg/kg via IV infusion on Day 1 of each cycle (21 days), every 3 weeks until RECIST v1.1-defined PD, withdrawal of consent, or until any other of the discontinuation criteria was met.
| Group | Source count |
|---|---|
| T-DXd | 102 |
Reported measurements
Survival rate at 6 months
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| T-DXd | 67.6 | Not reported | 57.4 | 75.9 | Not reported |
Survival rate at 12 months
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| T-DXd | 46.3 | Not reported | 35.7 | 56.3 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 57.4
- upper Limit
- 75.9
- value
- 67.6
- title
- Survival rate at 6 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 35.7
- upper Limit
- 56.3
- value
- 46.3
- title
- Survival rate at 12 months
- denoms
- counts
- group Id
- OG000
- value
- 102
- units
- Participants
- description
- Percentage of participants alive at 6 and 12 months are reported. It was calculated using the Kaplan-Meier technique. CI for median PFS derived based on the Brookmeyer-Crowley method.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants harboring tumors with specific HER2 activating mutations received T-DXd 5.4 mg/kg via IV infusion on Day 1 of each cycle (21 days), every 3 weeks until RECIST v1.1-defined PD, withdrawal of consent, or until any other of the discontinuation criteria was met.
- id
- OG000
- title
- T-DXd
- param Type
- NUMBER
- population Description
- The FAS consisted of all participants who received at least 1 dose of study treatment.
- reporting Status
- POSTED
- time Frame
- At Months 6 and 12
- title
- Percentage of Participants Alive at 6 and 12 Months
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice